NCT03502681 2022-07-01A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer PatientsBig Ten Cancer Research ConsortiumPhase 1 Terminated6 enrolled 12 charts